Radiopharm Theranostics has begun a Phase 1 clinical trial for its RAD 402 candidate to treat advanced prostate cancer [1, 2].
This development represents a shift toward theranostics, a personalized medical approach that combines targeted radiation imaging and therapy. By locating and destroying cancer cells while sparing healthy tissue, the method aims to increase treatment efficacy and reduce side effects [3, 5].
Approval to initiate the Phase 1 therapeutic trial of RAD 402 was announced Nov. 18, 2025 [1]. Following that regulatory milestone, the company dosed the first patient in the study on March 27, 2026 [2]. Radiopharm Theranostics, headquartered in Sydney, Australia, is listed on the Australian Securities Exchange under the ticker ASX:RAD [1].
Parallel to the clinical trials, researchers at the University of Missouri's Cancer Targeted Technology and Isotherapeutics Group have addressed the challenge of manufacturing these personalized drugs. The team developed a new automated production method that reduces the time required to create drug candidates [3].
According to the study, automation cut the production time for a prostate-cancer drug candidate from six hours to 38 minutes [3]. This reduction in manufacturing time is critical because radiopharmaceuticals often have short half-lives, meaning they decay quickly after production.
Medical professionals, including Dr. Geoffrey Johnson and Dr. Ephraim Parent of the Mayo Clinic, are involved in the broader application of these theranostic techniques [4]. The integration of faster production and targeted delivery is designed to make these complex therapies more affordable, and widely available to patients globally [3, 5].
“Automation cut the production time for a prostate-cancer drug candidate from six hours to 38 minutes.”
The convergence of clinical trials for new candidates like RAD 402 and the automation of drug production addresses the two primary hurdles of personalized medicine: efficacy and scalability. By reducing production time from hours to minutes, the medical community can overcome the volatile nature of radioactive isotopes, potentially transforming theranostics from a niche, high-cost intervention into a standard of care for advanced prostate cancer.
